TY - BOOK ID - 137069730 TI - Pharmacogenetics to Avoid Adverse Drug Reactions PY - 2022 PB - Basel MDPI - Multidisciplinary Digital Publishing Institute DB - UniCat KW - 5-fluorouracil KW - capecitabine KW - fluoropyrimidine KW - thymidylate synthase KW - thymidylate synthase enhancer region KW - upstream stimulatory factor 1 KW - adverse drug reactions KW - pharmacogenomics KW - epistasis KW - random forest KW - statin KW - cardiovascular disease KW - colorectal cancer KW - personalised medicine KW - toxicity KW - (es)citalopram KW - drug-gene-interaction KW - drug-drug-interaction KW - drug-drug-gene-interaction KW - the PharmLines initiative KW - antipsychotic agents KW - pharmacogenetics KW - cytochrome P-450 enzyme system KW - psychotic disorders KW - precision medicine KW - direct oral anticoagulants KW - clinical implementation KW - atorvastatin KW - SLCO1B1 KW - HLA KW - cutaneous adverse drug reaction KW - SCAR KW - genetic polymorphism KW - antiepileptics KW - CYP450 enzymes KW - platelet reactivity KW - single-nucleotide variants KW - acute coronary syndrome KW - clopidogrel KW - genotype KW - allele KW - polymorphism KW - HLA B KW - CYP2C9*3 KW - cutaneous adverse drug reactions (CADRs) KW - anti-epileptic drugs (AEDS) KW - phenytoin (PHT) KW - genetic risk factors KW - South India KW - India KW - cardiology KW - adverse events KW - guidelines KW - n/a UR - https://www.unicat.be/uniCat?func=search&query=sysid:137069730 AB - Adverse drug reactions are one of the major constraints when using drugs. These adverse reactions can impact healthcare systems as strongly as many prevalent diseases. Identifying DNA variants associated with adverse drug reactions can help personalize medicine and sustain healthcare systems. This book delves into new advances in pharmacogenetics of cardiovascular, cancer, and nervous system drugs. It may be useful for clinicians and patients to understand the basics of pharmacogenetics. ER -